Bronchiectasis
-
Explore the Latest Developments in Bronchiectasis During ATS 2026 Orlando
on
Read more: Explore the Latest Developments in Bronchiectasis During ATS 2026 OrlandoIn August 2025, clinicians and researchers who treat patients with bronchiectasis reached a significant milestone with the FDA approval of brensocatib, the first treatment developed for non-cystic fibrosis bronchiectasis in adults and pediatric patients aged 12 and older. In an interview with ATS Conference News, Dan Belz, MD, MPH, explained the significance of this milestone…
-
Bronchiectasis and COPD Lineup at ATS 2026 Orlando
on
Read more: Bronchiectasis and COPD Lineup at ATS 2026 OrlandoATS 2026 Orlando offers a robust scientific program, featuring a variety of scientific symposia, abstract presentations, and Meet the Expert sessions to examine the latest investigative insights and clinical challenges for treating bronchiectasis and COPD.